Skip to main content

Pacritinib Approved for Intermediate- or High-Risk Myelofibrosis With Thrombocytopenia

The FDA has approved pacritinib (VonjoTM, CTI BioPharma) for the treatment of adult patients with intermediate- to high-risk primary or secondary myelofibrosis with a platelet count below 50x109/L. Pacritinib is a novel oral kinase inhibitor which inhibits Janus kinase 2 (JAK2) with minimal myelosuppression. Previous treatments available for intermediate- and high-risk myelofibrosis have not been approved for patients with severe cytopenia. "Pacritinib can provide a treatment option for patients...

Continue reading

Lusutrombopag Approved for Thrombocytopenia in Adults With Liver Disease

The FDA has issued approval for lusutrombopag (Mulpleta, Shionogi Inc.) for the treatment of thrombocytopenia in adult patients with chronic liver disease prior to an invasive medical or dental procedure. Thrombocytopenia can cause heavy bleeding and other surgical complications due to low platelet count. Approval was based on results from 2 randomized, double-blind, placebo-controlled trials involving 312 patients with chronic liver disease and a platelet count less than 50 x 109/L who were sch...

Continue reading